149 research outputs found
Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak
N/
Yellow Plugs: An Additional Dermoscopic Criterion in the Diagnosis of Primary Cutaneous B-Cell Lymphoma
n/
Evidence for proton acceleration and escape from the Puppis A SNR using Fermi-LAT observations
Supernova remnants (SNRs) are the best candidates for galactic cosmic ray
acceleration to relativistic energies via diffusive shock acceleration. The
gamma-ray emission of SNRs can provide direct evidence of leptonic (inverse
Compton and bremsstrahlung) and hadronic (proton-proton interaction and
subsequently pion decay) processes. Puppis A is a ~ 4 kyr old SNR interacting
with interstellar clouds which has been observed in a broad energy band, from
radio to gamma-ray. We performed a morphological and spectral analysis of 14
years of observations with Fermi-LAT telescope in order to study its gamma-ray
emission. We found a clear asymmetry in high-energy brightness between the
eastern and western sides of the remnant, reminiscent to that observed in the
X-ray emission. The eastern side, interacting with a molecular cloud, shows a
spectrum which can be reproduced by a pion decay model. Moreover, we analyzed
two gamma-ray sources located close to the remnant. The hardness of their
spectra suggests that the gamma-ray emission can be due to particles escaping
from the shock of Puppis A.Comment: Presented at the 38th International Cosmic Ray Conference (ICRC
2023), 8 pages, 2 figures, 3 table
An overview of treatment options for mild-to-moderate acne based on American Academy of Dermatology, European Academy of Dermatology and Venereology, and Italian Society of Dermatology and Venereology guidelines
Acne is a common inflammatory skin disorder affecting the pilosebaceous unit. Patients with mild-to-moderate acne can be treated with a combination of topical, systemic, and physical therapeutic approaches, with different results depending on patient, disease, and treatment characteristics. Herein we describe and discuss the common and alternative treatment options used for mild-to-moderate acne, by comparing three widely distributed guidelines (American Academy of Dermatology, European Academy of Dermatology and Venereology, and Italian Society of Dermatology and Venereology
Clinical and Dermoscopic Features of Melanocytic Lesions on the Face Versus the External Ear
Introduction
Melanoma of the external ear is a rare condition accounting for 7-20% of all melanomas of the head and neck region. They present classical features of extra-facial melanomas clinically and dermoscopically. In contrast, facial melanomas show peculiar patterns in dermoscopy.
Objectives
To evaluate whether there are clinical and/or dermoscopic differences in melanocytic lesions located either at the external ear or on the face.
Methods
In this retrospective study we reviewed an image database for clinical and dermoscopic images of melanomas and nevi located either on the face or at the level of the external ear.
Results
65 patients (37 men; 63.8%) with 65 lesions were included. We found no significant differences in comparing face melanomas with melanomas at the level of the external ear, neither clinically nor dermoscopically. However, we provided evidence for differences in some clinical and dermoscopic features of melanomas and nevi of the external ear.
Conclusions
In this study, we reported no significant differences in comparing melanomas on the face with melanomas of the external ear, both clinically and dermoscopically. Furthermore, we provided data on clinical and dermoscopic differences comparing nevi and melanoma of the external ear
Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent nonmelanoma skin cancer (NMSC). The majority of in situ cSCC [cSCC (Tis)] can be cured surgically, while local advanced and metastatic ones require other treatments, but there are no therapies approved by U.S. Food and Drug Administration (FDA). Available treatments for these stages included radiotherapy, chemotherapy as cisplatin, but responses to these treatments are usually of short duration. Programmed death-1 (PD-1) inhibitors (pembrolizumab, nivolumab, and cemiplimab) are an innovative immunologic treatment that now has been shown to be useful for the treatment of advanced cSCC. Nowadays, data about the response rate with the use of PD-1 inhibitors in cSCC are still few and, especially, the duration of the response after the start of treatment is short. Moreover, the number of cases is too small to express the beneficial effects of these treatments, although most data reported in the literature show quite good response rates. This review focused on some of the studies and associated results through an interesting research on search engines of all the cases about these systemic drugs, analyzing effects and side effects, and the research has been conducted considering published cases since March 2016 to October 2019
- …